Cancer drug screening: the historical perspective

July 21st, 2018 Posted by Publications 0 thoughts on “Cancer drug screening: the historical perspective”

Chemotherapy with cytotoxic and growth inhibitory drugs have played an important role in cancer therapy, used either alone or in combination with other treatment modalities such as surgery, radiation or biological therapy. Chemotherapy, in most instances, was the only alternative treatment for metastatic cancer – mainly given as drug combinations…

(more…)

ScreenIn3D chosen to receive ‘Innovation AveNEW’ grant to appear at SLAS Europe

June 15th, 2018 Posted by Events 0 thoughts on “ScreenIn3D chosen to receive ‘Innovation AveNEW’ grant to appear at SLAS Europe”

Innovation AveNEW is a traditional highlight of the annual SLAS Conference and Exhibition. Through this program, SLAS provides start-up companies with tremendous exposure and prestige by granting complimentary exhibit space and in-kind support that enables the company’s participation at the SLAS Annual Conference & Exhibition.

(more…)

Beyond Limitations: New Microfluidics Platform for Cancer Drug Screening and Profiling

May 29th, 2018 Posted by Publications 0 thoughts on “Beyond Limitations: New Microfluidics Platform for Cancer Drug Screening and Profiling”

High-attrition rates during clinical development of new cancer therapies still persist. A new 3D ex vivo microfluidics platform shall now enhance cancer drug screening and early development process by creating cancer models which predict clinical outcomes with significantly increased reliability.

Read the full article

Subscribe to Blog

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Our Company
Follow Us

 

© Copyright AMS Biotechnology (Ltd) / University of Strathclyde / ScreenIn3D. All rights reserved 2018.